Search

Your search keyword '"Puig, L."' showing total 2,471 results

Search Constraints

Start Over You searched for: Author "Puig, L." Remove constraint Author: "Puig, L."
2,471 results on '"Puig, L."'

Search Results

1. Defining the Care Pathway in Patients with Psoriasis and Atopic Dermatitis

4. [Artículo traducido] Tratamiento comparativo de lesiones mucocutáneas en pacientes con telangiectasia hemorrágica hereditaria con láser dual secuencial de colorante pulsado y neodimio: itrio-aluminio-granate versus neodimio: itrio-aluminio-granate solo: un estudio controlado aleatorizado doble ciego con evaluación de la calidad de vida

6. Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives

8. AB1136 INCREASE OF IL10 AND IFNA2 ARE ASSOCIATED TO CLINICAL ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOUS PATIENTS

9. AB0880 PROGNOSTIC SIGNIFICANCE OF DISEASE DURATION, AGE, AND PERSISTENT INFLAMMATION IN AORTIC VALVE DEGENERATIVE LESIONS AMONG PATIENTS WITH SPONDYLOARTHRITIS

10. AB0957 PROFILE OF REAL WORLD AXIAL SPONDYLOARTHRITIS PATIENTS REFRACTORY TO ADVANCED THERAPY

11. AB1010 DRUG-INDUCED LUPUS: CLINICAL AND SEROLOGICAL FEATURES IN A TERTIARY HOSPITAL

12. AB0750 ASSOCIATION OF ANTI-CarP LEVELS WITH THE SEROLOGICAL PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS

13. The thermal architecture of the ESA ARIEL payload at the end of phase B1

21. Analyse intégrée, issue de 26 études cliniques, des infections fongiques apparues sous traitement chez les patients atteints de psoriasis, de rhumatisme psoriasique ou de spondyloarthrite axiale traités par ixékizumab

28. An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis.

30. Comparative Treatment of Mucocutaneous Lesions in Hereditary Haemorrhagic Telangiectasia Patients With Dual Sequential Pulsed Dye Laser and Neodymium: Yttrium-Aluminium-Garnet Versus Neodymium: Yttrium-Aluminium-Garnet Laser Alone: A Double-Blind Randomized Controlled Study With Quality-of-Life Evaluation

34. Risk of severe COVID-19 associated with immune-modifying drugs: Data from PsoProtect and Global Rheumatology Alliance registries.

35. AB0928 USE OF RITUXIMAB IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY AND DIFFUSE CUTANEOUS INVOLVEMENT. A SERIES OF 15 CASES

36. POS0645 REAL LIFE SAFETY AND SURVIVAL OF TARGETED THERAPIES IN ARTHRITIS PATIENTS OVER AGE OF 65

37. OP0062 EULAR POINTS TO CONSIDER FOR THE DEFINITION OF CLINICAL AND IMAGING FEATURES SUSPICIOUS FOR PROGRESSION TO PSORIATIC ARTHRITIS

38. AB1337 COVID-19 AND JAKI: ANALYSIS AFTER THREE-YEAR PANDEMIC AT A SPANISH TERTIARY CARE HOSPITAL

39. AB1150 ORDER OF APPEARANCE OF PSORIASIS AND ARTHRITIS SYMPTOMS IN PSORIATIC ARTHRITIS: COMPARATIVE STUDY OF A RETROSPECTIVE COHORT

40. AB1587 EXPERIENCE IN REAL-WORLD CONDITIONS OF THE EFFECTIVENESS OF THE VACCINE AGAINST HERPES ZOSTER

41. AB0476 AFTER JAK INHIBITOR FAILURE, ‘SWITCHING’ OR ‘CYCLING’?

42. AB1424 CLINICAL VARIABILITY IN PATIENTS DIAGNOSED OF JUVENILE IDIOPATHIC ARTHRITIS WITH POSITIVE AND NEGATIVE ANTINUCLEAR ANTIBODIES (ANA)

43. AB1236 OSTEOPOROSIS AND FRACTURES IN PATIENTS UNDERGOING CHRONIC CORTICOSTEROID THERAPY

44. AB0426 PROFILE OF REFRACTORY RA PATIENTS FOR TARGETED THERAPIES IN REAL LIFE

46. Diversity in the clinical presentation of generalized pustular psoriasis (GPP): A series of case vignettes from around the world

Catalog

Books, media, physical & digital resources